Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study

• Published in: Epilepsia (Copenhagen) Vol. 62; no. 12; pp. 3005 - 3015
• Main Authors: Sperling, Michael R., Abou‐Khalil, Bassel, Aboumatar, Sami, Bhatia, Perminder, Biton, Victor, Klein, Pavel, Krauss, Gregory L., Vossler, David G., Wechsler, Robert, Ferrari, Louis, Grall, Mindy, Rosenfeld, William E.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-12-2021; John Wiley and Sons Inc
• Subjects: Adult; Adverse events; Anticonvulsants - therapeutic use; Carbamates; cenobamate; Chlorophenols; Convulsions & seizures; Double-Blind Method; Drug Therapy, Combination; efficacy; focal epilepsy; Full‐length Original Research; Humans; long term; Patients; safety/tolerability; Seizures; Seizures - chemically induced; Seizures - drug therapy; Tetrazoles; Titration; Treatment Outcome; focal epilepsy; long term; safety/tolerability; efficacy; cenobamate
• ISSN: 0013-9580; 1528-1167
• DOI: 10.1111/epi.17091

Objective
To report long‐term post hoc efficacy and safety data from 10 US study sites from an open‐label Phase 3 study of adjunctive cenobamate (NCT02535091).
Methods
Patients with uncontrolled focal seizures taking stable doses of 1–3 antiseizure medications (ASMs) were administered increasing daily doses of cenobamate (12.5, 25, 50, 100, 150, 200 mg/day) over 12 weeks at 2‐week intervals (target dose = 200 mg/day). Further increases to 400 mg/day by 50‐mg/day increments biweekly were allowed during the maintenance phase. Dose adjustments of cenobamate and concomitant ASMs were allowed. Data were assessed until the last clinic visit on or after September 1, 2019.
Results
Of 255 patients, 240 with focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic seizure data while on treatment were evaluated (median [maximum] exposure = 30.2 [43.0] months across the entire study). Median baseline seizure frequency/28 days was 2.8 (mean = 18.1). Of the 240 patients, 177 (73.8%) were continuing cenobamate treatment at data cutoff. The ≥50% responder rate for the total treatment duration was 71.7% (172/240). During titration, the ≥50% responder rates were 48.1% during Weeks 1–4 (12.5–25 mg/day cenobamate) and 61.7% during Weeks 5–8 (50–100 mg/day cenobamate). Among all patients who received a dose of cenobamate in the maintenance phase (n = 214), 13.1% (28/214) and 40.2% (86/214) achieved 100% and ≥90% seizure reduction during their entire maintenance treatment duration (median = 29.5 months). Among all patients, 87 (36.3%) had any consecutive ≥12‐month duration of 100% seizure reduction. Common treatment‐emergent adverse events among all 240 patients included fatigue (34.6%), dizziness (32.1%), and somnolence (29.6%).
Significance
This post hoc analysis of a subset of patients from the long‐term open‐label study showed high rates of sustained 100% and ≥90% seizure reduction, with many achieving response early during titration. These findings suggest durable seizure frequency reduction with cenobamate in adults with uncontrolled focal seizures.